Eli Lilly and Co
Change company Symbol lookup
Select an option...
LLY Eli Lilly and Co
INTC Intel Corp
DVN Devon Energy Corp
CCL Carnival Corp
OKE ONEOK Inc
BMY Bristol-Myers Squibb Co
KO Coca-Cola Co
DOW Dow Inc
CTVA Corteva Inc
COP Conocophillips
Go

Health Care : Pharmaceuticals | Large Cap Growth
Company profile

Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.

Closing Price
$365.25
Day's Change
3.53 (0.98%)
Bid
--
Ask
--
B/A Size
--
Day's High
365.83
Day's Low
361.55
Volume
(Light)
Volume:
1,039,094

10-day average volume:
3,176,973
1,039,094

Barclays Resumes Further Issuances and Sales of Certain iPath(R) ETNs

7:12 am ET September 19, 2022 (BusinessWire) Print

Barclays Bank PLC ("Barclays Bank") announced today that it plans to resume further issuances and sales by Barclays Bank and its affiliates of each series of iPath(R) ETNs (the "ETNs") listed in the table below, effective as of the open of trading on Monday, September 26, 2022. This action follows the announcements by Barclays Bank on March 14, 2022, April 22, 2022 and April 28, 2022 to suspend sales of the ETNs. As Barclays Bank indicated in its announcement on August 1, 2022, further issuances and sales of the ETNs are being resumed now that the rescission offer has been completed and settlement of the rescission offer with respect to the ETNs has occurred. Further issuances and sales of the ETNs will be made pursuant to Barclays Bank's shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on May 23, 2022. As described below, this action may result in fluctuations in the trading value of the ETNs.

                                        Name of ETN                                       Ticker  Exchange    CUSIP
----------------------------------------------------------------------------------------- ------ --------- ---------
iPath(R) Series B S&P 500(R) VIX Short-Term Futures(TM) ETN   VXX   CBOE BZX  06747R477
----------------------------------------------------------------------------------------- ------ --------- ---------
iPath(R) Pure Beta Crude Oil ETN                                             OIL   NYSE Arca 06740P221
----------------------------------------------------------------------------------------- ------ --------- ---------
Pacer(R) iPath(R) Gold Trendpilot ETN                        PBUG   NYSE Arca 06747T382
----------------------------------------------------------------------------------------- ------ --------- ---------
iPath(R) Series B Bloomberg Natural Gas Subindex Total Return(SM) ETN        GAZ   NYSE Arca 06745T368
----------------------------------------------------------------------------------------- ------ --------- ---------
iPath(R) Series B Carbon ETN                                                 GRN   NYSE Arca 06747C322
----------------------------------------------------------------------------------------- ------ --------- ---------

The market value of the ETNs may be influenced by, among other things, the levels of supply and demand for such ETNs. Recently, a premium or discount, as the case may be, has developed in the trading price of certain series of ETNs in relation to the intraday indicative value of such series. It is possible that this reopening of sales and issuances, or the announcement thereof, may influence the trading price of the ETNs or cause the premium or discount to decrease or to no longer be present, though it is not possible to predict such impact. In particular, if an investor paid a premium purchase price over the indicative value of the ETNs, it could lead to significant losses in the event an investor sells ETNs at a time when such premium is no longer present in the marketplace or if Barclays Bank redeems the ETNs at its discretion.

The pricing supplement and prospectus relating to each series of ETNs can be found on EDGAR, the SEC website at www.sec.gov, as well as on the product website at the product page for each of the ETNs listed in the tables above at ipathetn.barclays.

An investment in the ETNs involves significant risks and may not be suitable for all investors. The ETNs are riskier than ordinary unsecured debt securities and do not benefit from any principal protection. For more information on risks associated with the ETNs, please see "Selected Risk Considerations" below and the risk factors included in the relevant pricing supplement.

Barclays Bank is the issuer of the ETNs and Barclays Capital Inc. is the issuer's agent in the distribution. Please contact Barclays Bank for further questions:

Financial advisors: Directly contact Barclays Bank at etndesk@barclays.com or 1-212-528-7990 to obtain further information. Individual investors: Instruct your broker/advisor/custodian to email us at etndesk@barclays.com or to call us at: 1-212-528-7990. You may call in together with your broker/advisor/custodian or have them speak to us on your behalf.

About Barclays

Barclays is a British universal bank. We are diversified by business, by different types of customers and clients, and by geography. Our businesses include consumer banking and payments operations around the world, as well as a full-service corporate and investment bank. For further information about Barclays, please visit our website www.barclays.com.

Selected Risk Considerations

An investment in the ETNs described herein involves risks. Selected risks are summarized here, but we urge you to read the more detailed explanation of risks described under "Risk Factors" in the applicable prospectus supplement and pricing supplement.

You May Lose Some or All of Your Principal: The ETNs are exposed to any change in the level of the underlying index between the inception date and the applicable valuation date. Additionally, if the level of the underlying index is insufficient to offset the negative effect of the investor fee and other applicable costs, you will lose some or all of your investment at maturity or upon redemption, even if the value of such index has increased or decreased, as the case may be. Because the ETNs are subject to an investor fee and other applicable costs, the return on the ETNs will always be lower than the total return on a direct investment in the index components. The ETNs are riskier than ordinary unsecured debt securities and have no principal protection.

Credit of Barclays Bank PLC: The ETNs are unsecured debt obligations of Barclays Bank PLC and are not, either directly or indirectly, an obligation of or guaranteed by any third party. Any payment to be made on the ETNs, including any payment at maturity or upon redemption, depends on the ability of Barclays Bank PLC to satisfy its obligations as they come due. As a result, the actual and perceived creditworthiness of Barclays Bank PLC will affect the market value, if any, of the ETNs prior to maturity or redemption. In addition, if Barclays Bank PLC were to default on its obligations, you may not receive any amounts owed to you under the terms of the ETNs.

Issuer Redemption: If specified in the applicable prospectus, Barclays Bank PLC will have the right to redeem or call the ETNs (in whole but not in part) at its sole discretion and without your consent on any trading day on or after the inception date until and including maturity.

Market and Volatility Risk: The market value of the ETNs may be influenced by many unpredictable factors and may fluctuate between the date you purchase them and the maturity date or redemption date. You may also sustain a significant loss if you sell your ETNs in the secondary market. Factors that may influence the market value of the ETNs include prevailing market prices of the commodity markets, the U.S. stock markets or the U.S. Treasury market, the index components included in the underlying index, and prevailing market prices of options on such index or any other financial instruments related to such index; and supply and demand for the ETNs, including economic, financial, political, regulatory, geographical or judicial events that affect the level of such index or other financial instruments related to such index.

A Trading Market for the ETNs May Not Develop: Although the ETNs are listed on a U.S. national securities exchange, a trading market for the ETNs may not develop and the liquidity of the ETNs may be limited, as we are not required to maintain any listing of the ETNs.

No Interest Payments from the ETNs: You may not receive any interest payments on the ETNs.

Restrictions on the Minimum Number of ETNs and Date Restrictions for Redemptions: Except as specified in the pricing supplement, you must redeem at least the minimum number of ETNs specified in the pricing supplement at one time in order to exercise your right to redeem your ETNs on any redemption date. You may only redeem your ETNs on a redemption date if we receive a notice of redemption from you by certain dates and times as set forth in the pricing supplement.

Uncertain Tax Treatment: Significant aspects of the tax treatment of the ETNs are uncertain. You should consult your own tax advisor about your own tax situation.

The ETNs may be sold throughout the day on the exchange through any brokerage account. Commissions may apply and there are tax consequences in the event of sale, redemption or maturity of ETNs. Sales in the secondary market may result in significant losses.

Barclays Bank PLC has filed a registration statement (including a base prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the base prospectus for this offering in that registration statement and other documents Barclays Bank PLC has filed with the SEC for more complete information about Barclays Bank PLC and this offering. You may get these documents for free by searching the SEC online database (EDGAR) at www.sec.gov. Alternatively, you may obtain a copy of the base prospectus from Barclays Bank PLC by calling toll-free 1-888-227-2275 (extension 7-7990).

(C) 2022 Barclays Bank PLC. All rights reserved. iPath, iPath ETNs and the iPath logo are registered trademarks of Barclays Bank PLC. All other trademarks, servicemarks or registered trademarks are the property, and used with the permission, of their respective owners.

 NOT FDIC INSURED --  NO BANK GUARANTEE --  MAY LOSE VALUE
-------------------------------------------------------------------------------

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005454/en/

SOURCE: Barclays Bank PLC

Ann Thielke
+1 212 526 1472
Ann.Thielke@barclays.com
comtex tracking

COMTEX_414785802/1006/2022-09-19T07:12:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.